Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | CETP | P11597 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078580 | 1.00 | GBA1 (0.42) | GBA1LPAR3LPAR1LPAR2PPARG | |
| SCHEMBL3081569 | 0.98 | GBA1 (0.45) | GBA1LPAR3LPAR1LPAR2PPARG | |
| SCHEMBL3073791 | 0.98 | GBA1 (0.45) | GBA1LPAR3LPAR1LPAR2PPARG | |
| SCHEMBL3078679 | 0.95 | GBA1 (0.36) | GBA1LPAR3LPAR1LPAR2PPARG | |
| SCHEMBL3069602 | 0.95 | GBA1 (0.36) | GBA1LPAR3LPAR1LPAR2PPARG | |
| SCHEMBL3080523 | 0.89 | PDPK1 (0.36) | CETPTSHRALDH1A1LMNA | |
| SCHEMBL3075490 | 0.89 | PDPK1 (0.36) | CETPTSHRALDH1A1LMNA | |
| SCHEMBL3088916 | 0.82 | GBA1 (0.46) | GBA1LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL3086913 | 0.82 | GBA1 (0.46) | GBA1LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL3078423 | 0.81 | GBA1 (0.49) | GBA1LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | disclosed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | GBA1 2176/4885LPAR3 1154/4885LPAR1 2004/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | GBA1 91/4885LPAR3 3383/4885LPAR1 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.